Han Wu, Weng Kai, Zhang Peipei, Hong Zhinuan
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University, Fuzhou, China.
Front Surg. 2023 Jan 4;9:1091601. doi: 10.3389/fsurg.2022.1091601. eCollection 2022.
Neoadjuvant immunochemotherapy (nICT) has been confirmed with promising pathological complete response (pCR) among locally advanced esophageal squamous cell carcinoma (ESCC). However, there were still no reliable and accurate predictors to predict the treatment response. This study aimed to explore the predictive value of inflammatory and nutritional parameters.
Patients with ESCC who underwent radical surgery after nICT between January 2020 and April 2022 were included in the study. First, the least absolute shrinkage and selection operator regression (LASSO) logistic regression analysis was used to screen independent inflammatory and nutritional parameters. Secondly, univariate and multivariate logistic regression were used to screen and predict independent risk factors for pCR. Thirdly, a nomogram was constructed based on the independent predictive factors, and 30% of the included population was randomly selected as the validation cohort. We used the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) curve to evaluate the nomogram model.
A total of 97 ESCC patients were screened for analysis, with 20 patients with pCR (20.32%). Only the systemic immune-inflammation index (SII) was screened after LASSO-logistic regression when was 0.06. The cut-off value of SII was 921.80 with an area under curve (AUC) value of 0.62. We defined SII > 921.80 as high SII and SII ≦ 921.80 as low SII. Further, the univariate and multivariate analysis further determined SII(OR = 3.94, 95%CI:1.26-12.42, = 0.02) and clinical stage(OR = 0.35, 95%CI:0.12-0.98, = 0.05) were independent predictive factors of pCR. One novel nomogram was established with an AUC value of 0.72 in the training cohort and 0.82 in the validation cohort. The Brier score of the calibration curve was 0.13. The calibration curve showed good agreement between the predicted results and the actual results in both the training cohort and the validation cohort. Compared with the clinical stage, the DCA confirmed a better clinical value of the nomogram model in both the training cohort and the validation cohort.
High pretreatment SII and early clinical stage were independently associated with pCR among ESCC receiving nICT. We further established and validated one novel nomogram model to effectively predict pCR among ESCC after nICT.
新辅助免疫化疗(nICT)已被证实在局部晚期食管鳞状细胞癌(ESCC)中具有良好的病理完全缓解(pCR)效果。然而,仍没有可靠且准确的预测指标来预测治疗反应。本研究旨在探讨炎症和营养参数的预测价值。
纳入2020年1月至2022年4月期间接受nICT后行根治性手术的ESCC患者。首先,采用最小绝对收缩和选择算子回归(LASSO)逻辑回归分析筛选独立的炎症和营养参数。其次,采用单因素和多因素逻辑回归筛选并预测pCR的独立危险因素。第三,基于独立预测因素构建列线图,并从纳入人群中随机抽取30%作为验证队列。我们使用受试者工作特征(ROC)曲线、校准曲线和决策曲线分析(DCA)曲线来评估列线图模型。
共筛选出97例ESCC患者进行分析,其中20例患者达到pCR(20.32%)。LASSO逻辑回归筛选后,当λ为0.06时,仅筛选出全身免疫炎症指数(SII)。SII的截断值为921.80,曲线下面积(AUC)值为0.62。我们将SII > 921.80定义为高SII,SII≤921.80定义为低SII。进一步的单因素和多因素分析进一步确定SII(OR = 3.94,95%CI:1.26 - 12.42,P = 0.02)和临床分期(OR = 0.35,95%CI:0.12 - 0.98,P = 0.05)是pCR的独立预测因素。建立了一个新的列线图,在训练队列中的AUC值为0.72,在验证队列中的AUC值为0.82。校准曲线的Brier评分为0.13。校准曲线显示训练队列和验证队列中预测结果与实际结果之间具有良好的一致性。与临床分期相比,DCA证实列线图模型在训练队列和验证队列中均具有更好的临床价值。
接受nICT的ESCC患者中治疗前高SII和早期临床分期与pCR独立相关。我们进一步建立并验证了一个新的列线图模型,以有效预测nICT后ESCC患者的pCR。